Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events and non-fatal stroke in patients with type 2 diabetes mellitus.

Practitioners should consider GLP-1RAs as a therapeutic option for reducing cardiovascular risks in patients with type 2 diabetes.

GLP-1RAs are being studied in clinical settings not previously examined in original trials.

Practitioners should stay informed about the evolving applications of GLP-1RAs in clinical practice.

The management of type 2 diabetes (T2D) has evolved significantly with the emergence of diverse medication classes.

Healthcare professionals should be aware of the evolving medication landscape for T2D.

Naltrexone/bupropion may benefit sexual desire through mood improvement.

Practitioners might consider Naltrexone/bupropion for patients seeking improvements in sexual desire linked to mood.

DPP-4 inhibitors offer stroke prevention and cognitive advantages, particularly in patients with renal impairment.

DPP-4 inhibitors may be considered for patients at risk of stroke and cognitive decline.

GLP-1RA therapy was associated with a lower risk of all-cause mortality in nondiabetic patients with PAD (HR: 0.40; 95% CI: 0.35–0.46; p < 0.001).

GLP-1RAs may help reduce overall mortality in patients with PAD who do not have diabetes.

GLP-1RA therapy was associated with a lower risk of major adverse limb events (MALE) in nondiabetic patients with PAD (HR: 0.22; 95% CI: 0.17–0.28; p < 0.001).

GLP-1RAs may reduce the risk of serious limb complications in patients with PAD who do not have diabetes.

GIP and GLP-1 may modify glucagon secretion, impacting cardiac substrate utilization.

Understanding the role of GIP and GLP-1 in glucagon secretion can help tailor treatments for cardiac health in T2D.

Simultaneous activation of GLP-1 and GIP receptors may result in synergistic and additive effects on glycemic control.

Combining therapies that target both GLP-1 and GIP receptors may improve treatment outcomes for diabetes.

A prescrição de suplementação alimentar nem sempre é realizada com orientação correta por profissionais adequados.

É crucial que a suplementação seja orientada por nutricionistas para evitar riscos à saúde.

High glycemic index (GI) meals require 1.5-fold more insulin to maintain similar glycemia compared to low GI meals.

Practitioners should consider the increased insulin needs when recommending high GI foods to individuals with T1D.

Postprandial hyperglycemia, rather than insulin level, mediates the activation of brain areas associated with food cravings.

Understanding that hyperglycemia drives cravings can help in managing dietary choices for individuals with diabetes.

Pharmacological treatments, particularly GLP-1 agonists, have shown promising results but are limited by lack of cost coverage.

Practitioners should be aware of the potential benefits of GLP-1 agonists while considering the financial implications for patients.

Tirzepatide has a favorable safety profile but requires further investigation.

Practitioners should consider tirzepatide as a treatment option while monitoring for adverse reactions.

Ambulatory blood pressure monitoring strengthens the association between blood pressure control and cardiovascular outcomes.

Utilizing ambulatory BP monitoring may improve cardiovascular risk assessment in patients treated with GLP-1RA.

Amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators.

Amylin receptor activators may be a safer alternative to GLP-1 receptor activators for patients.

An exploratory every-8-weeks regimen showed attenuated efficacy compared to once-monthly dosing.

Practitioners should consider monthly dosing as more effective than less frequent regimens.

Gut-derived hormones, the central nervous system, and pancreatic function interact to maintain energy homeostasis.

Understanding the interplay of these systems can inform strategies for addressing metabolic disorders.

Adverse events were more frequent in the semaglutide group, including gastrointestinal intolerance and infections.

Clinicians should be aware of the higher incidence of adverse events with semaglutide.

The benefits of GLP-1R agonists may be enhanced by stimulating other receptors.

Combining GLP-1R agonists with other receptor agonists may enhance therapeutic outcomes.

Maximal and sustained benefit of GLP-1 receptor agonists may be compromised by poor compliance and cessation of use.

Practitioners should address compliance issues when prescribing GLP-1 receptor agonists.

GLP-1 RA users had higher rates of cardiovascular complications (RR = 1.426, p = 0.038).

Practitioners should monitor cardiovascular health in patients using GLP-1 RAs.

The Deep Reinforcement Learning (DRL) agent decreased gastrointestinal (GI) adverse events incidence by 35% and severity by 42% in simulations.

Implementing a DRL agent for dosing may significantly reduce GI side effects in patients.

Medication adherence increased from 52.8% to 84%.

Encouraging medication adherence can significantly improve patient outcomes.